Validation of a model to predict severity and prognosis in acute pulmonary embolism
Multicenter Prospective Validation and Extension of the 'PUMCH' Acute Pulmonary Embolism Severity and Prognosis Prediction Model
This study is testing a new way to predict how serious acute pulmonary embolism is and what the outcomes might be for adults diagnosed with it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05723003 on ClinicalTrials.gov |
What this trial studies
This study aims to validate a prediction model for assessing the severity and prognosis of acute pulmonary embolism (PE) using multi-center data. It involves enrolling patients aged 18 and older who have been diagnosed with acute PE through various imaging techniques. The study collects comprehensive demographic, clinical, and imaging data, and follows patients over time to evaluate survival outcomes. The model will be optimized using artificial intelligence clustering algorithms to enhance its predictive capabilities.
Who should consider this trial
Good fit: Ideal candidates for this study are inpatients aged 18 years or older diagnosed with acute pulmonary embolism.
Not a fit: Patients who are unable to complete follow-up due to cognitive or behavioral limitations may not benefit from this study.
Why it matters
Potential benefit: If successful, this model could significantly improve the prognosis and management of patients with acute pulmonary embolism.
How similar studies have performed: While this approach is based on existing data, the use of artificial intelligence for model optimization in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years * Inpatients with acute PTE diagnosed by imaging (CTPA, enhanced CT, V/Q imaging suggesting a high probability of PE, pulmonary angiography, MRPA) containing any of the following conditions. 1. primary acute PTE combined with or without DVT 2. recurrent acute PTE with a history of previous PTE or DVT * signed informed consent form Exclusion Criteria: * blinded to any diagnostic or therapeutic test (VTE or other conditions) * unable to complete follow-up (due to cognitive or behavioral limitations, etc.)
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Juhong Shi, M.D — Peking Union Medical College Hospital
- Study coordinator: Juhong Shi, M.D
- Email: shijh@pumch.cn
- Phone: +8613701178492
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.